Norwegian children are receiving weight-loss injections at dramatically higher rates. A national health institute report shows prescriptions jumped from just six cases to 717 over five years.
These medications are officially approved for Norwegian youth aged 12 to 17. The sharp increase began around 2020 and continues through last year.
GLP-1 analog medications dominate these prescriptions. Senior researcher Øystein Karlstad explained how these drugs work in a health institute publication.
He said the injections increase insulin sensitivity and secretion. They also suppress hunger, boost feelings of fullness, and lead to reduced calorie intake.
The statistics come from the Norwegian Institute of Public Health's database. They reveal a clear trend toward pharmaceutical interventions for childhood obesity.
Why are doctors turning to these medications for younger patients? The data suggests a shift in treating weight issues among Norwegian youth.
These numbers represent real children receiving weekly or monthly injections. The trend raises questions about long-term health impacts on developing bodies.
Norway faces the same global challenge of rising childhood obesity rates. But their approach now includes pharmaceutical solutions at unprecedented scale.